{"id":"standard-of-care-docetaxel","safety":{"commonSideEffects":[{"rate":"75–80%","effect":"Neutropenia"},{"rate":"5–10%","effect":"Anemia"},{"rate":"5–10%","effect":"Thrombocytopenia"},{"rate":"20–35%","effect":"Peripheral neuropathy"},{"rate":"75–80%","effect":"Alopecia"},{"rate":"30–40%","effect":"Nausea and vomiting"},{"rate":"30–40%","effect":"Diarrhea"},{"rate":"15–20%","effect":"Mucositis"},{"rate":"40–50%","effect":"Fatigue"},{"rate":"2–5%","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Standard of Care: Docetaxel","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:32:27.968695+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:32:35.015845+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Standard of Care: Docetaxel","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:32:35.751475+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL339519/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:32:36.781488+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by arresting cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis. It is effective against rapidly dividing cancer cells across multiple tumor types.","oneSentence":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:24.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:32:38.618213+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric adenocarcinoma"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT04337580","phase":"PHASE2","title":"Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-05","conditions":"Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer","enrollment":50},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT05848011","phase":"PHASE2","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MacroGenics","startDate":"2023-09-28","conditions":"Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent","enrollment":154},{"nctId":"NCT06841055","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-03-03","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT06635824","phase":"PHASE3","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2024-11-25","conditions":"PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC","enrollment":191},{"nctId":"NCT06881784","phase":"PHASE3","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2025-05-06","conditions":"NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC","enrollment":420},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT07442565","phase":"PHASE3","title":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-03-10","conditions":"Non-Small Cell Lung Cancer","enrollment":506},{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT06446882","phase":"NA","title":"Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2024-10-11","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":304},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT06937905","phase":"PHASE3","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02-06","conditions":"Neuroendocrine Carcinoma","enrollment":129},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT06815497","phase":"PHASE2","title":"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2026-01-21","conditions":"Ovarian Cancer","enrollment":33},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT07365995","phase":"PHASE3","title":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":736},{"nctId":"NCT07358806","phase":"PHASE1","title":"Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Oscotec Inc.","startDate":"2025-12-18","conditions":"Solid Tumor, Breast Cancer, Head and Neck Cancer","enrollment":51},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT06879717","phase":"PHASE1, PHASE2","title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOnctura","startDate":"2025-04-22","conditions":"Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC","enrollment":45},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT03556904","phase":"PHASE2","title":"FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-12-10","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":34},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":"Carcinoma, Non-Small -Cell Lung","enrollment":300},{"nctId":"NCT07333976","phase":"PHASE2","title":"o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2020-01-05","conditions":"Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neurotoxicity","enrollment":90},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT05704829","phase":"PHASE2","title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2024-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":402},{"nctId":"NCT05450692","phase":"PHASE3","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":594},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT05132075","phase":"PHASE3","title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-06-15","conditions":"Non-Small Cell Lung Cancer","enrollment":95},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT07222657","phase":"PHASE2","title":"Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer","enrollment":40},{"nctId":"NCT06929286","phase":"PHASE3","title":"A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-11","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":125},{"nctId":"NCT07220135","phase":"PHASE2","title":"Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-11-14","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT05446870","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-25","conditions":"High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma","enrollment":160},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT05733351","phase":"PHASE1","title":"Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-08-03","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":4},{"nctId":"NCT05076760","phase":"PHASE1","title":"MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Memgen, Inc.","startDate":"2022-04-21","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":40},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":162},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT04527991","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-01-13","conditions":"Locally Advanced or Metastatic Unresectable Urothelial Cancer","enrollment":712},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07076693","phase":"PHASE2, PHASE3","title":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-06-03","conditions":"OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer","enrollment":97},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT03884556","phase":"PHASE1","title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2019-04-10","conditions":"Solid Tumor, Lymphoma","enrollment":56},{"nctId":"NCT06940180","phase":"PHASE2","title":"Toripalimab With Chemotherapy for Sinus Cancer","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2025-06-17","conditions":"Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT04115007","phase":"PHASE3","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-23","conditions":"Oligometastatic Hormone Sensitive Prostate Cancer","enrollment":550},{"nctId":"NCT03739710","phase":"PHASE2","title":"Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-01-24","conditions":"Neoplasms","enrollment":175},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06955702","phase":"NA","title":"Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Salamanca","startDate":"2023-11-15","conditions":"Breast Neoplasms, Alopecia, Madarosis","enrollment":120},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT05925491","phase":"PHASE2","title":"Pembrolizumab in Locally Advanced Sinonasal Carcinoma","status":"RECRUITING","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2024-12-24","conditions":"Sinonasal Undifferentiated Carcinoma","enrollment":28},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT02288247","phase":"PHASE3","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":688},{"nctId":"NCT05800587","phase":"PHASE2","title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-02-22","conditions":"Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT04553692","phase":"PHASE1","title":"Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2020-09-23","conditions":"Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma","enrollment":272},{"nctId":"NCT06768931","phase":"PHASE2","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-30","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer","enrollment":192},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT02908477","phase":"PHASE3","title":"Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-10-03","conditions":"Oropharynx Cancer","enrollment":228},{"nctId":"NCT03763253","phase":"PHASE2","title":"Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imperial College London","startDate":"2019-04-10","conditions":"Prostate Cancer, Metastatic Prostate Cancer","enrollment":433},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT05348577","phase":"PHASE3","title":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-25","conditions":"Prostate Cancer","enrollment":1035},{"nctId":"NCT03769506","phase":"PHASE3","title":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2019-05-09","conditions":"Head and Neck Cancer","enrollment":135},{"nctId":"NCT02723955","phase":"PHASE1","title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-23","conditions":"Neoplasms","enrollment":829}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL339519"},"_approvalHistory":[],"publicationCount":962,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere®"],"phase":"marketed","status":"active","brandName":"Standard of Care: Docetaxel","genericName":"Standard of Care: Docetaxel","companyName":"H. Lee Moffitt Cancer Center and Research Institute","companyId":"h-lee-moffitt-cancer-center-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:32:38.618213+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}